TY - JOUR
T1 - AUD in perspective
AU - de Bejczy, Andrea
AU - Addolorato, Giovanni
AU - Aubin, Henri-Jean
AU - Guiraud, Julien
AU - Korpi, Esa R
AU - John Nutt, David
AU - Witkiewitz, Katie
AU - Söderpalm, Bo
PY - 2024
Y1 - 2024
N2 - Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and treating AUD cannot be overstated. Given the global burden and the high attributable factor of alcohol in a vast number of diseases, the need for additional interventions and the development of new medicines is considered a priority by the World Health Organization (WHO). As of today, AUD is severely under-treated with a treatment gap nearing 90%, strikingly higher than that for other psychiatric disorders. Patients often seek treatment late in the progress of the disease and even among those who seek treatment only a minority receive medication, mirroring the still-prevailing stigma of the disease, and a lack of access to effective treatments, as well as a reluctance to total abstinence. To increase adherence, treatment goals should focus not only on maintaining abstinence, but also on harm reduction and psychosocial functioning. A personalised approach to AUD treatment, with a holistic view, and tailored therapy has the potential to improve AUD treatment outcomes by targeting the heterogeneity in genetics and pathophysiology, as well as reason for, and reaction to drinking. Also, the psychiatric co-morbidity rates are high in AUD and dual diagnosis can worsen symptoms and influence treatment response and should be considered in the treatment strategies.
AB - Alcohol is a major cause of pre-mature death and individual suffering worldwide, and the importance of diagnosing and treating AUD cannot be overstated. Given the global burden and the high attributable factor of alcohol in a vast number of diseases, the need for additional interventions and the development of new medicines is considered a priority by the World Health Organization (WHO). As of today, AUD is severely under-treated with a treatment gap nearing 90%, strikingly higher than that for other psychiatric disorders. Patients often seek treatment late in the progress of the disease and even among those who seek treatment only a minority receive medication, mirroring the still-prevailing stigma of the disease, and a lack of access to effective treatments, as well as a reluctance to total abstinence. To increase adherence, treatment goals should focus not only on maintaining abstinence, but also on harm reduction and psychosocial functioning. A personalised approach to AUD treatment, with a holistic view, and tailored therapy has the potential to improve AUD treatment outcomes by targeting the heterogeneity in genetics and pathophysiology, as well as reason for, and reaction to drinking. Also, the psychiatric co-morbidity rates are high in AUD and dual diagnosis can worsen symptoms and influence treatment response and should be considered in the treatment strategies.
KW - AUD diagnosis
KW - Co-morbidity
KW - Harm reduction
KW - Personalized medicine
KW - Public health
KW - Treatment gap
KW - Treatment goal
KW - AUD diagnosis
KW - Co-morbidity
KW - Harm reduction
KW - Personalized medicine
KW - Public health
KW - Treatment gap
KW - Treatment goal
UR - https://publicatt.unicatt.it/handle/10807/314150
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85188090672&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85188090672&origin=inward
U2 - 10.1016/bs.irn.2024.03.003
DO - 10.1016/bs.irn.2024.03.003
M3 - Article
SN - 0074-7742
VL - 175
SP - 1
EP - 19
JO - International Review of Neurobiology
JF - International Review of Neurobiology
IS - N/A
ER -